BR112015011933A8 - Composições bacterianas sinérgicas e métodos de produção e uso das mesmas - Google Patents

Composições bacterianas sinérgicas e métodos de produção e uso das mesmas

Info

Publication number
BR112015011933A8
BR112015011933A8 BR112015011933A BR112015011933A BR112015011933A8 BR 112015011933 A8 BR112015011933 A8 BR 112015011933A8 BR 112015011933 A BR112015011933 A BR 112015011933A BR 112015011933 A BR112015011933 A BR 112015011933A BR 112015011933 A8 BR112015011933 A8 BR 112015011933A8
Authority
BR
Brazil
Prior art keywords
synergic
production
methods
bacterial compositions
compositions
Prior art date
Application number
BR112015011933A
Other languages
English (en)
Other versions
BR112015011933A2 (pt
Inventor
Von Maltzahn Geoffrey
R HENN Matthew
Mario D'onofrio Anthony
Daniel Litcofsky Kevin
a berry David
Cook David
B Afeyan Noubar
G Aunins John
Original Assignee
Seres Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seres Therapeutics Inc filed Critical Seres Therapeutics Inc
Publication of BR112015011933A2 publication Critical patent/BR112015011933A2/pt
Publication of BR112015011933A8 publication Critical patent/BR112015011933A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/127—Antibiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

COMPOSIÇÕES BACTERIANAS SINÉRGICAS E MÉTODOS DE PRODUÇÃO E USO DAS MESMAS. São fornecidas composições terapêuticas que contêm populações ecobioticTM para prevenção, tratamento e redução dos sintomas associados com uma disbiose de um sujeito mamífero, tal como um humano.
BR112015011933A 2012-11-23 2013-11-25 Composições bacterianas sinérgicas e métodos de produção e uso das mesmas BR112015011933A8 (pt)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
US201261729520P 2012-11-23 2012-11-23
US201261729525P 2012-11-23 2012-11-23
US201261729517P 2012-11-23 2012-11-23
US201261729518P 2012-11-23 2012-11-23
US201261729524P 2012-11-23 2012-11-23
US201261729527P 2012-11-23 2012-11-23
US201261729515P 2012-11-23 2012-11-23
US201261729521P 2012-11-23 2012-11-23
US201261729519P 2012-11-23 2012-11-23
US201261729526P 2012-11-23 2012-11-23
US201261729522P 2012-11-23 2012-11-23
US61/729.526 2012-11-23
US61/729.519 2012-11-23
US61/729.517 2012-11-23
US61/729.524 2012-11-23
US61/729.522 2012-11-23
US61/729.525 2012-11-23
US61/729.518 2012-11-23
US61/729.515 2012-11-23
US61/729.527 2012-11-23
US61/729.520 2012-11-23
US61/729.521 2012-11-23
PCT/US2013/071758 WO2014082050A1 (en) 2012-11-23 2013-11-25 Synergistic bacterial compositions and methods of production and use thereof

Publications (2)

Publication Number Publication Date
BR112015011933A2 BR112015011933A2 (pt) 2018-05-15
BR112015011933A8 true BR112015011933A8 (pt) 2022-09-20

Family

ID=50776593

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015011933A BR112015011933A8 (pt) 2012-11-23 2013-11-25 Composições bacterianas sinérgicas e métodos de produção e uso das mesmas

Country Status (20)

Country Link
US (1) US20230226126A1 (pt)
EP (3) EP4233545A3 (pt)
JP (3) JP6506173B2 (pt)
KR (2) KR102426653B1 (pt)
CN (1) CN104955466A (pt)
AU (4) AU2013347805C1 (pt)
BR (1) BR112015011933A8 (pt)
CA (3) CA2892297C (pt)
DK (1) DK3628161T3 (pt)
ES (1) ES2949659T3 (pt)
FI (1) FI3628161T3 (pt)
HK (1) HK1218836A1 (pt)
IL (1) IL238973A0 (pt)
MX (1) MX2015006491A (pt)
NZ (1) NZ709392A (pt)
PL (1) PL3628161T3 (pt)
PT (1) PT3628161T (pt)
RU (1) RU2724666C2 (pt)
SG (2) SG10201704035TA (pt)
WO (1) WO2014082050A1 (pt)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011209940B2 (en) 2010-02-01 2015-08-20 Mikrobex Inc. Bacteriotherapy for clostridium difficile colitis
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CN104780932A (zh) 2012-02-29 2015-07-15 伊西康内外科公司 微生物区系的组合物及与其相关的方法
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
CN110917220A (zh) 2013-02-04 2020-03-27 赛里斯治疗公司 治疗组合物及其使用方法
EP2951283A4 (en) 2013-02-04 2017-01-25 Seres Therapeutics, Inc. Compositions and methods
EP2967077A4 (en) 2013-03-15 2016-09-14 Seres Therapeutics Inc MICROBIAL COMPOSITIONS AND ASSOCIATED METHODS BASED ON A NETWORK
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
JP6330032B2 (ja) 2013-06-05 2018-05-23 レビオティクス インコーポレイテッドＲｅｂｉｏｔｉｘ，Ｉｎｃ． 微生物叢回復療法組成物を製造、処理、および梱包するための方法
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
CN105407728A (zh) 2013-07-21 2016-03-16 霍勒拜欧姆公司 用于微生物组表征、监测和治疗的方法和系统
CN116370507A (zh) 2013-11-25 2023-07-04 赛里斯治疗公司 协同细菌组合物以及其制造方法和用途
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
EP3212001A4 (en) 2014-10-31 2018-04-25 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
SG10202105996WA (en) 2014-12-23 2021-07-29 4D Pharma Res Ltd Pirin polypeptide and immune modulation
KR20220151045A (ko) 2014-12-23 2022-11-11 4디 파마 리서치 리미티드 면역 조정
IL281424B2 (en) 2015-06-09 2023-10-01 Rebiotix Inc Microbiota restoration treatment preparations and production methods
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
RS59308B1 (sr) 2015-06-15 2019-10-31 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PL3206700T3 (pl) 2015-06-15 2019-11-29 4D Pharma Res Ltd Kompozycje zawierające szczepy bakteryjne
MA41060B1 (fr) * 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MD3240554T2 (ro) 2015-06-15 2020-01-31 4D Pharma Res Ltd Blautia stercosis și wexlerae pentru utilizare în tratarea bolilor inflamatorii și autoimune
CN108348558A (zh) * 2015-07-08 2018-07-31 赛里斯治疗公司 治疗结肠炎的方法
CN105012350B (zh) * 2015-08-06 2018-09-25 温州医科大学 益生菌丁酸梭菌菌株
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
ME03003B (me) 2015-11-20 2018-10-20 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
KR20180083894A (ko) * 2015-11-24 2018-07-23 세레스 테라퓨틱스, 인코포레이티드 설계된 박테리아 조성물
WO2017091694A1 (en) 2015-11-24 2017-06-01 Memorial Sloan-Kettering Cancer Center Methods and compositions for identifying and treating subjects at risk for checkpoint blockade therapy associated colitis
EP3379935A4 (en) * 2015-11-25 2019-08-28 Memorial Sloan-Kettering Cancer Center METHOD AND COMPOSITIONS FOR REDUCING VANCOMYCIN RESISTANT ENTEROKOKKEN
PL3407903T3 (pl) * 2016-01-25 2021-12-20 Novozymes A/S Sposób zmniejszania zakwitu drobnoustrojów w wylęgarni drobiu
FI3639834T3 (fi) 2016-02-04 2023-09-27 Univ Gent Mikrobiyhteisöjen käyttö ihmisen ja eläimen terveyttä varten
JP7327773B2 (ja) * 2016-03-04 2023-08-16 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 微生物共同体およびその使用
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
RS58869B1 (sr) 2016-03-04 2019-08-30 4D Pharma Plc Kompozicije koje sadrže blautia bakterijske sojeve za lečenje visceralne hipersenzitivnosti
CN110545828A (zh) * 2016-04-19 2019-12-06 基因组研究有限公司 细菌疗法
CN107460140B (zh) * 2016-06-02 2020-11-13 浙江科技学院 一种芽孢杆菌hz16中抑制军团菌活性物的制备方法
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
WO2018027898A1 (zh) * 2016-08-12 2018-02-15 深圳华大基因研究院 一种产丁酸栖粪杆菌及其培养方法和应用
EP3511407B1 (en) * 2016-09-06 2023-05-17 BGI Shenzhen Christensenella intestinihominis and application thereof
EP3511406A4 (en) * 2016-09-06 2020-04-01 BGI Shenzhen FAECALIBACTERIUM LONGUM AND ASSOCIATED APPLICATION
KR101978068B1 (ko) * 2016-11-25 2019-08-28 서울대학교산학협력단 신규한 페디오코커스 악시딜락티시를 이용한 돼지 설사증 예방 또는 치료용 조성물
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
EP3378949A1 (en) * 2017-03-22 2018-09-26 Assistance Publique - Hôpitaux de Paris Method for determining the potential efficacy of anticancer treatment
TWI787272B (zh) 2017-05-22 2022-12-21 英商4D製藥研究有限公司 包含細菌菌株之組合物
JP6978514B2 (ja) 2017-05-24 2021-12-08 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited 細菌株を含む組成物
JP6884889B2 (ja) 2017-06-14 2021-06-09 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
KR20200015575A (ko) 2017-06-14 2020-02-12 4디 파마 리서치 리미티드 세균 균주를 포함하는 조성물
JP2020530840A (ja) 2017-08-14 2020-10-29 セレス セラピューティクス インコーポレイテッド 胆汁うっ滞性疾患を治療するための組成物及び方法
CN111372596A (zh) 2017-08-30 2020-07-03 潘德勒姆治疗公司 用于治疗微生物组相关病症的方法和组合物
CN111432825A (zh) 2017-10-03 2020-07-17 赛里斯治疗公司 色胺代谢的操纵
AU2019253714A1 (en) 2018-04-10 2020-11-26 Siolta Therapeutics, Inc. Microbial consortia
TW202014513A (zh) 2018-05-11 2020-04-16 英商4D製藥研究有限公司 包含細菌菌株之組合物
CA3112501A1 (en) * 2018-09-10 2020-03-19 Riken Composition for inhibiting trypsin activity containing as active ingredient bacterium belonging to genus paraprevotella
WO2020055193A1 (en) * 2018-09-14 2020-03-19 Industry-Academic Cooperation Foundation, Yonsei University Microorganism with antibacterial activity for enteric pathogenic bacteria and pharmaceutical composition for preventing and treating enteric pathogenic bacteria induced disease using the same
IT201900006056A1 (it) * 2019-04-18 2020-10-18 Probiotical Spa Procedimento per la preparazione di una biomassa di cellule di batteri liofilizzate stabili e determinazione della loro stabilità mediante un metodo citofluorimetrico
KR102064134B1 (ko) * 2019-09-10 2020-01-08 재단법인 농축산용미생물산업육성지원센터 신균주 페디오코쿠스 에시딜락티시 cacc 537 및 이를 유효성분으로 함유하는 반려동물용 사료 조성물
EP4041264A1 (en) 2019-10-07 2022-08-17 Siolta Therapeutics, Inc. Therapeutic pharmaceutical compositions
IL271778A (en) * 2019-12-31 2021-06-30 Ichilov Tech Ltd Methods for treating atopic dermatitis
EP4102984A1 (en) * 2020-02-10 2022-12-21 Native Microbials, Inc. Microbial compositions and methods of use for canine enteropathy and dysbiosis
IL296218A (en) * 2020-03-10 2022-11-01 Federation Bio Inc A microbial mixture to treat the disease
CN111991404B (zh) * 2020-10-10 2021-08-13 西南医科大学 防治真菌感染的复合维生素d及其应用
AU2022312473A1 (en) * 2021-07-10 2024-02-29 Microba Ip Pty Ltd Compositions and methods for treating disease ii
CN113549671B (zh) * 2021-07-21 2023-09-08 连云港市第一人民医院 一种诊断维持性血液透析患者肌少症的肠道菌群
CN114438133B (zh) * 2022-02-15 2023-10-27 合肥工业大学 菊粉发酵物、其制备方法及在防治动物结肠癌中的用途
WO2023199057A1 (en) 2022-04-13 2023-10-19 Brunel University London Compositions for preventing and treating infection comprising an artificial sweetener
KR102620190B1 (ko) * 2022-08-31 2024-01-04 주식회사 바이오뱅크힐링 아가토박터 렉탈리스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
CN115305226B (zh) * 2022-09-22 2023-06-16 郑州轻工业大学 一株降解烟碱并产氢的抗辐射不动杆菌zj-22及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839281A (en) 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
JP2961182B2 (ja) * 1990-03-09 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
JP2961184B2 (ja) * 1990-05-07 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
RU2035186C1 (ru) * 1992-07-09 1995-05-20 Семен Рафаилович Резник Профилактический биопрепарат споролакт
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US20030118547A1 (en) * 2000-01-27 2003-06-26 Vandenberg Grant William Composition for intestinal delivery
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
CN1294253C (zh) * 2000-11-30 2007-01-10 生物平衡公司 细菌菌株，加工过的植物提取物，含有它们的组合物，其制备方法及其治疗和工业应用
ITMI20011632A1 (it) * 2001-07-27 2003-01-27 Sanofi Synthelabo Composizione solida contenente spore di batteri non patogeni del genere bacillus
MXPA06001821A (es) * 2003-08-18 2006-05-31 Bio Balance Corp Una composicion probiotica, liquida, estable, preparacion y aplicaciones de la misma.
EP2035544A2 (en) * 2006-05-18 2009-03-18 Biobalance Llc Bacterial strains, compositions including same and probiotic use thereof
EE05459B1 (et) * 2006-12-08 2011-08-15 Tartu �likool Sporogeense Bacillus smithii tvi TBMI12 MSCL P737 ja selle endospooride kasutamine probiootikumina, toidulisandina ning probiootiline kompositsioon
CA2785658C (en) * 2009-12-31 2017-10-24 Ira Milton Trachtman Compositions and method for treatment and prophylaxis of inflammatory bowel disease
US9492487B2 (en) * 2010-02-01 2016-11-15 Matthew Ryan Garner Microbial product containing multiple microorganisms
CA2811056A1 (en) * 2010-09-10 2012-03-15 Viropharma Incorporated Environmental clostridial bacteriotherapy and related formulations and methods of manufacture and use
EP2672980B1 (en) * 2011-02-09 2017-12-06 Lavivo AB Synbiotic compositions for restoration and reconstitution of gut microbiota
WO2012142605A1 (en) * 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent

Also Published As

Publication number Publication date
JP6506173B2 (ja) 2019-04-24
DK3628161T3 (da) 2023-05-30
EP2953472A4 (en) 2017-03-01
AU2013347805C1 (en) 2018-06-28
JP2022028787A (ja) 2022-02-16
RU2724666C2 (ru) 2020-06-25
JP6978463B2 (ja) 2021-12-08
WO2014082050A1 (en) 2014-05-30
KR102617655B1 (ko) 2023-12-27
AU2013347805A1 (en) 2015-07-09
PL3628161T3 (pl) 2023-08-07
JP2015537042A (ja) 2015-12-24
JP2019135240A (ja) 2019-08-15
EP3628161B1 (en) 2023-04-05
CA2892297A1 (en) 2014-05-30
US20230226126A1 (en) 2023-07-20
AU2018204406B2 (en) 2019-12-05
KR20150108357A (ko) 2015-09-25
FI3628161T3 (fi) 2023-05-25
HK1218836A1 (zh) 2017-03-17
CA3212772A1 (en) 2014-05-30
CA3212215A1 (en) 2014-05-30
AU2020201598B2 (en) 2022-03-24
JP7491643B2 (ja) 2024-05-28
SG11201503966PA (en) 2015-06-29
EP4233545A2 (en) 2023-08-30
KR20220108205A (ko) 2022-08-02
KR102426653B1 (ko) 2022-07-28
NZ709392A (en) 2016-10-28
AU2022204478A1 (en) 2022-07-14
AU2020201598C1 (en) 2022-07-07
CA2892297C (en) 2023-10-24
BR112015011933A2 (pt) 2018-05-15
IL238973A0 (en) 2015-07-30
RU2015124366A (ru) 2017-01-10
AU2020201598A1 (en) 2020-03-19
AU2018204406A1 (en) 2018-07-05
EP3628161A1 (en) 2020-04-01
ES2949659T3 (es) 2023-10-02
CN104955466A (zh) 2015-09-30
PT3628161T (pt) 2023-05-15
SG10201704035TA (en) 2017-06-29
AU2013347805B2 (en) 2018-04-05
EP2953472A1 (en) 2015-12-16
EP4233545A3 (en) 2023-10-18
MX2015006491A (es) 2015-12-03

Similar Documents

Publication Publication Date Title
BR112015011933A8 (pt) Composições bacterianas sinérgicas e métodos de produção e uso das mesmas
MX2019009132A (es) Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
AR092475A1 (es) Metodos para tratar la dermatitis atopica mediante la administracion de un antagonista de il-4r
MX365835B (es) Uso de akkermansia para tratar trastornos metabolicos.
DOP2015000039A (es) Inhibidores de glucosilceramida sintasa
ECSP13012978A (es) Inhibidores de glucosilceramida sintasa
PE20141906A1 (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
BR112012020558A2 (pt) moduladores do receptor de androgênio e seus usos
AR089993A1 (es) Macrociclos peptidomimeticos
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
GB201106750D0 (en) Novel compounds
GB201106743D0 (en) Novel compounds
IN2014MN01736A (pt)
MY185016A (en) Progenitor cells of mesodermal lineage
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
BR112015029386A8 (pt) uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit
CL2016000150A1 (es) Compuestos y composiciones como inhibidores de la mek
MX2013004061A (es) Analogos de ciclosporina.
NZ701949A (en) Combination treatments and compositions for wound healing
IN2014DN06104A (pt)
MX2013013649A (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
MX2013004062A (es) Analogos de ciclosporina.
BR112014027047A2 (pt) nova formulação

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 63/00 , A01N 65/00

Ipc: A61K 35/742 (2015.01), A61P 1/12 (2006.01), A61P 1

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]